FR18C1032I2 - ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT - Google Patents

ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Info

Publication number
FR18C1032I2
FR18C1032I2 FR18C1032C FR18C1032C FR18C1032I2 FR 18C1032 I2 FR18C1032 I2 FR 18C1032I2 FR 18C1032 C FR18C1032 C FR 18C1032C FR 18C1032 C FR18C1032 C FR 18C1032C FR 18C1032 I2 FR18C1032 I2 FR 18C1032I2
Authority
FR
France
Prior art keywords
pharmaceutical composition
fgf23 antibodies
fgf23
antibodies
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1032C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of FR18C1032I1 publication Critical patent/FR18C1032I1/fr
Application granted granted Critical
Publication of FR18C1032I2 publication Critical patent/FR18C1032I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
FR18C1032C 2007-02-14 2018-07-27 ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT Active FR18C1032I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
PCT/JP2008/052918 WO2008099969A1 (en) 2007-02-14 2008-02-14 Anti-fgf23 antibody and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
FR18C1032I1 FR18C1032I1 (en) 2018-08-31
FR18C1032I2 true FR18C1032I2 (en) 2019-08-09

Family

ID=39690189

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1032C Active FR18C1032I2 (en) 2007-02-14 2018-07-27 ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Country Status (23)

Country Link
US (4) US7883705B2 (en)
EP (3) EP2502996B1 (en)
JP (1) JP4800396B2 (en)
KR (1) KR101462291B1 (en)
CN (2) CN102702355B (en)
AU (1) AU2008215346B2 (en)
CA (1) CA2677782C (en)
CY (3) CY1118835T1 (en)
DK (3) DK2502996T3 (en)
ES (3) ES2625823T3 (en)
FR (1) FR18C1032I2 (en)
HK (2) HK1140228A1 (en)
HR (2) HRP20170548T1 (en)
HU (3) HUE050517T2 (en)
LT (3) LT3181691T (en)
LU (2) LUC00082I2 (en)
NL (1) NL300945I2 (en)
NO (1) NO2018025I1 (en)
PL (3) PL2128253T3 (en)
PT (3) PT2502996T (en)
SI (2) SI3181691T1 (en)
TW (1) TWI422593B (en)
WO (1) WO2008099969A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344679T3 (en) * 2000-08-11 2010-09-03 Kyowa Hakko Kirin Co., Ltd. POLYPEPTIDES THAT CONTROL THE METABOLISM OF PHOSPHORIC ACID, THE METABOLISM OF CALCIUM, THE METABOLISM OF CALCIFICATION AND VITAMIN D AND DNA MOLECULES THAT CODIFY THEM.
WO2003057733A1 (en) * 2001-12-28 2003-07-17 Kirin Beer Kabushiki Kaisha Antibodies against fibroblast growth factor 23
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
EP2723391B1 (en) 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
EP3845245A1 (en) * 2014-06-09 2021-07-07 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
EP3604517A4 (en) 2017-03-30 2020-12-16 Sysmex Corporation Anti-apoa1 antibody
CN113950355A (en) * 2019-03-29 2022-01-18 阿塔盖有限责任公司 Antibody molecules to FGF23 and uses thereof
WO2024034638A1 (en) * 2022-08-10 2024-02-15 協和キリン株式会社 Anti-fgf23 antibody, and fragment of said antibody

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (en) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
JP2958019B2 (en) 1988-05-06 1999-10-06 住友製薬株式会社 Polyethylene glycol derivative, modified peptide and method for producing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
TWI227734B (en) 1998-05-18 2005-02-11 Univ London A novel polypeptide hormone phosphatonin
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
AU3924300A (en) 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666494A1 (en) 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001042451A2 (en) 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
CA2396401A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
US20030149238A1 (en) 2000-02-14 2003-08-07 Pankaj Agarwal Novel compounds
CA2398603A1 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002008271A1 (en) * 2000-07-19 2002-01-31 Advanced Research & Technology Institute Novel fibroblast growth factor (fgf23) and methods for use
ES2344679T3 (en) * 2000-08-11 2010-09-03 Kyowa Hakko Kirin Co., Ltd. POLYPEPTIDES THAT CONTROL THE METABOLISM OF PHOSPHORIC ACID, THE METABOLISM OF CALCIUM, THE METABOLISM OF CALCIFICATION AND VITAMIN D AND DNA MOLECULES THAT CODIFY THEM.
DE60131456T2 (en) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
AU2002302581A1 (en) * 2001-04-26 2002-11-11 Geneprot, Inc. Human fibroblast growth factor-related compositions
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
WO2003057733A1 (en) 2001-12-28 2003-07-17 Kirin Beer Kabushiki Kaisha Antibodies against fibroblast growth factor 23
US7094551B2 (en) * 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JPWO2004083425A1 (en) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 Periodontal treatment
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
RS51326B (en) * 2004-08-05 2010-12-31 Genentech Inc. Humanized anti-cmet antagonists
CA2579391C (en) * 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
EP1849863A1 (en) 2005-01-21 2007-10-31 Kirin Pharma Kabushiki Kaisha Non-human chimeric animal and use thereof
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
KR20090114452A (en) 2009-11-03
JP4800396B2 (en) 2011-10-26
TWI422593B (en) 2014-01-11
HUS1800034I1 (en) 2018-09-28
US20190106485A1 (en) 2019-04-11
EP2502996A3 (en) 2013-04-10
AU2008215346B2 (en) 2013-01-10
CN102702355A (en) 2012-10-03
PL3181691T3 (en) 2020-11-02
CY2018021I1 (en) 2019-07-10
DK2128253T3 (en) 2015-01-05
EP2128253B1 (en) 2014-12-03
PL2502996T3 (en) 2017-07-31
HUE031728T2 (en) 2017-07-28
NO2018025I1 (en) 2018-08-09
PT2128253E (en) 2015-02-04
HRP20201266T1 (en) 2021-02-05
TW200902549A (en) 2009-01-16
CY1118835T1 (en) 2018-01-10
CA2677782C (en) 2016-07-26
HK1172917A1 (en) 2013-05-03
FR18C1032I1 (en) 2018-08-31
EP3181691B1 (en) 2020-07-15
LTC2502996I2 (en) 2019-05-10
PL2128253T3 (en) 2015-04-30
AU2008215346A1 (en) 2008-08-21
US20160159895A1 (en) 2016-06-09
ES2625823T3 (en) 2017-07-20
NL300945I1 (en) 2018-08-15
LUC00081I2 (en) 2018-10-01
WO2008099969A1 (en) 2008-08-21
CY1123240T1 (en) 2021-10-29
CN101652476B (en) 2012-07-04
EP3181691A1 (en) 2017-06-21
SI2502996T1 (en) 2017-08-31
LT3181691T (en) 2020-08-25
ES2811318T3 (en) 2021-03-11
EP2502996B1 (en) 2017-03-29
CN101652476A (en) 2010-02-17
HRP20170548T1 (en) 2017-08-25
ES2530670T3 (en) 2015-03-04
LUC00082I2 (en) 2018-10-01
PT2502996T (en) 2017-05-10
KR101462291B1 (en) 2014-11-14
PT3181691T (en) 2020-08-26
US20090148461A1 (en) 2009-06-11
DK2502996T3 (en) 2017-05-08
US9290569B2 (en) 2016-03-22
HK1140228A1 (en) 2010-10-08
JPWO2008099969A1 (en) 2010-05-27
LT2502996T (en) 2017-06-26
NL300945I2 (en) 2020-05-13
US7883705B2 (en) 2011-02-08
US10202446B2 (en) 2019-02-12
EP2502996A2 (en) 2012-09-26
LTPA2018508I1 (en) 2018-09-10
CA2677782A1 (en) 2008-08-21
EP2128253A1 (en) 2009-12-02
CY2018021I2 (en) 2019-07-10
US20110182913A1 (en) 2011-07-28
HUE050517T2 (en) 2020-12-28
CN102702355B (en) 2014-09-24
SI3181691T1 (en) 2020-09-30
EP2128253A4 (en) 2010-03-10
DK3181691T3 (en) 2020-08-17

Similar Documents

Publication Publication Date Title
FR18C1032I2 (en) ANTI-FGF23 ANTIBODIES AND PHARMACEUTICAL COMPOSITION COMPRISING IT
FR21C1040I1 (en) ANTI-CD20 ANTIBODY FORMULATIONS
FR14C0069I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE
FR21C1055I2 (en) COMPOSITION COMPRISING AN ANTI-INTERLEUKIN 13 ANTIBODY
FR2888850B1 (en) NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
DK2073795T3 (en) Abuse-safe drug formulation
ITBO20050123A1 (en) GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
MA28489B1 (en) PHARMACEUTICAL PREPARATIONS
NO20075628L (en) Pharmaceutical formulations
BRPI0821474A2 (en) stable liquid pharmaceutical formulation
BRPI0715712A2 (en) PHARMACEUTICAL COMPOSITION
ATE542815T1 (en) COCRYSTALS AND PHARMACEUTICAL COMPOSITIONS THEREOF
BRPI0719393A2 (en) Pharmaceutical Composition
CR10725A (en) PIRAZOLINE COMPOUNDS AND THEIR USE AND PHARMACEUTICAL COMPOSIONS
BRPI0716445A2 (en) pharmaceutical composition
FR2958157B1 (en) COSMETIC AND PHARMACEUTICAL COMPOSITION COMPRISING N-ACETYL-GLUCOSAMINE-6-PHOSPHATE
ATE530546T1 (en) COCRYSTALS AND PHARMACEUTICAL COMPOSITIONS THEREOF
FR2888748B1 (en) NEUROPROTECTIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
BRPI0615630A2 (en) pharmaceutical composition and use of sertindole
FR2912314B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODIES AGAINST THE HERV-W ENVELOPE
DE602006008023D1 (en) HEXOXY CERAMIDES AS ADJUVANTIES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS
MA28603B1 (en) ANTIMYCOBACTERIAL PHARMACEUTICAL COMPOSITION
FR2907786B1 (en) THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS
DK1886686T3 (en) Pharmaceutical composition containing mometasone furoate
BRPI0810057A2 (en) PHARMACEUTICAL COMPOSITION CONTAINING FLOROGLUCINOL AND PARACETAMOL